Research Articles | Page 8 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) Jul 2020 Leukemia Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Jan 2021 Leukemia Myelodysplastic Syndromes (MDS)
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index Sep 2020 Leukemia Myelodysplastic Syndromes (MDS)
High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag Jul 2020 Leukemia Aplastic Anemia
Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis Dec 2019 Leukemia Myelodysplastic Syndromes (MDS)
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Jan 2019 Leuk Lymphoma. Myelodysplastic Syndromes (MDS)
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial Aug 2020 Lancet Hematology Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)